Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Caplin

Drug and asset intelligence for Caplin with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 2
Stage: Development stage unavailable

Recent signals(4)

RegulatoryAugust 3, 2026

FDA Grants Approval for Calcium Gluconate by Caplin

The FDA has granted approval for Calcium Gluconate under application ANDA218840 submitted by Caplin.

RegulatoryAugust 1, 2026

FDA Grants AP Status for Fosaprepitant Dimeglumine ANDA203939

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Fosaprepitant Dimeglumine submitted by Caplin.

StrategyJuly 16, 2026

FDA Grants Approval for Foscarnet Sodium ANDA220068 by Caplin

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 220068 for Foscarnet Sodium submitted by Caplin.

RegulatoryJuly 12, 2026

FDA Accepts ANDA for Calcium Gluconate by Caplin

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Calcium Gluconate submitted by Caplin.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Caplin

July 16, 2026 · N/A

Topline Data

— Caplin

July 12, 2026 · N/A

Indications

Infectious Disease →

Therapeutic areas

Calcium Supplement →

Electrolyte Imbalance →

Electrolyte Imbalance · Calcium Supplement →

Infectious Disease →

Infectious Disease · Antiviral →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.